BioSpace News Archive

Milestone Pharmaceuticals Inc. announced that members of its management team will present at the following investor conferences.

Nanoscope Therapeutics Inc. announced that the International Nonproprietary Names Expert Committee of the World Health Organization has selected “sonpiretigene isteparvovec” for the nonproprietary name of the Company’s MCO-010, an ambient-light activatable Multi-Characteristic Opsin optogenetic monotherapy to restore vision in patients with retinitis pigmentosa and Stargardt disease.

Covalon Technologies Ltd. has announced that the annual and special meeting of shareholders of the Company will be held on Wednesday, March 8, 2023 at 3:30pm EST.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced its continued investment in endodontics, with a specific focus on clinical training and education.

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics® today announced significant progress updates for its two lead clinical development programs.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases.

ProQR Therapeutics N.V. announced that the Company will host a virtual R&D event on Wednesday, March 29, 2023 from 10:00 am until 12:30 pm EDT, including an Analyst Q&A session with members of the ProQR Management Team.

Spero Therapeutics, Inc. announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 43rd Annual Healthcare Conference.

Sutro Biopharma, Inc. today announced the appointment of Anne Borgman, M.D., as Chief Medical Officer, effective February 28, 2023.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update.